Benevolent News Hub

In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.

Our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease

Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedical research and how we can avoid the pitfalls.

For Mental Health Awareness Week, BenevolentAI’s in-house yogis and bioinformaticians evaluated the scientific research behind the effect of yoga on mental health.

BenevolentAI announced that baricitinib is entering clinical testing as a potential COVID-19 treatment. Benevolent identified the drug using its AI drug discovery platform. The trial by Eli Lilly will investigate the drug’s efficacy and safety.

BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.